155 related articles for article (PubMed ID: 22340283)
1. A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock.
Morris PE; Zeno B; Bernard AC; Huang X; Das S; Edeki T; Simonson SG; Bernard GR
Crit Care; 2012 Feb; 16(1):R31. PubMed ID: 22340283
[TBL] [Abstract][Full Text] [Related]
2. A Phase II study of polyclonal anti-TNF-α (AZD9773) in Japanese patients with severe sepsis and/or septic shock.
Aikawa N; Takahashi T; Fujimi S; Yokoyama T; Yoshihara K; Ikeda T; Sadamitsu D; Momozawa M; Maruyama T
J Infect Chemother; 2013 Oct; 19(5):931-40. PubMed ID: 23681364
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*.
Bernard GR; Francois B; Mira JP; Vincent JL; Dellinger RP; Russell JA; Larosa SP; Laterre PF; Levy MM; Dankner W; Schmitt N; Lindemann J; Wittebole X
Crit Care Med; 2014 Mar; 42(3):504-11. PubMed ID: 24335445
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic/pharmacodynamic modelling of the anti-TNF-α polyclonal fragment antibody AZD9773 in patients with severe sepsis.
Yates JW; Das S; Mainwaring G; Kemp J
J Pharmacokinet Pharmacodyn; 2012 Dec; 39(6):591-9. PubMed ID: 23001587
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis.
Rice TW; Wheeler AP; Morris PE; Paz HL; Russell JA; Edens TR; Bernard GR
Crit Care Med; 2006 Sep; 34(9):2271-81. PubMed ID: 16810105
[TBL] [Abstract][Full Text] [Related]
6. Determination of the safety and efficacy of therapeutic neutralization of tumor necrosis factor-α (TNF-α) using AZD9773, an anti-TNF-α immune Fab, in murine CLP sepsis.
Newham P; Ross D; Ceuppens P; Das S; Yates JW; Betts C; Reens J; Randall KJ; Knight R; McKay JS
Inflamm Res; 2014 Feb; 63(2):149-60. PubMed ID: 24240228
[TBL] [Abstract][Full Text] [Related]
7. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.
Abraham E; Laterre PF; Garbino J; Pingleton S; Butler T; Dugernier T; Margolis B; Kudsk K; Zimmerli W; Anderson P; Reynaert M; Lew D; Lesslauer W; Passe S; Cooper P; Burdeska A; Modi M; Leighton A; Salgo M; Van der Auwera P;
Crit Care Med; 2001 Mar; 29(3):503-10. PubMed ID: 11373411
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.
Abraham E; Wunderink R; Silverman H; Perl TM; Nasraway S; Levy H; Bone R; Wenzel RP; Balk R; Allred R
JAMA; 1995 Mar 22-29; 273(12):934-41. PubMed ID: 7884952
[TBL] [Abstract][Full Text] [Related]
9. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.
Abraham E; Glauser MP; Butler T; Garbino J; Gelmont D; Laterre PF; Kudsk K; Bruining HA; Otto C; Tobin E; Zwingelstein C; Lesslauer W; Leighton A
JAMA; 1997 May; 277(19):1531-8. PubMed ID: 9153367
[TBL] [Abstract][Full Text] [Related]
10. Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock.
Angstwurm MW; Engelmann L; Zimmermann T; Lehmann C; Spes CH; Abel P; Strauss R; Meier-Hellmann A; Insel R; Radke J; Schüttler J; Gärtner R
Crit Care Med; 2007 Jan; 35(1):118-26. PubMed ID: 17095947
[TBL] [Abstract][Full Text] [Related]
11. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.
Cohen J; Carlet J
Crit Care Med; 1996 Sep; 24(9):1431-40. PubMed ID: 8797612
[TBL] [Abstract][Full Text] [Related]
12. CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group.
Dhainaut JF; Vincent JL; Richard C; Lejeune P; Martin C; Fierobe L; Stephens S; Ney UM; Sopwith M
Crit Care Med; 1995 Sep; 23(9):1461-9. PubMed ID: 7664546
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the complex formed between a potent neutralizing ovine-derived polyclonal anti-TNFα Fab fragment and human TNFα.
Abbott WM; Snow M; Eckersley S; Renshaw J; Davies G; Norman RA; Ceuppens P; Slootstra J; Benschop JJ; Hamuro Y; Lee JE; Newham P
Biosci Rep; 2013 Aug; 33(4):. PubMed ID: 23863106
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.
Reinhart K; Wiegand-Löhnert C; Grimminger F; Kaul M; Withington S; Treacher D; Eckart J; Willatts S; Bouza C; Krausch D; Stockenhuber F; Eiselstein J; Daum L; Kempeni J
Crit Care Med; 1996 May; 24(5):733-42. PubMed ID: 8706447
[TBL] [Abstract][Full Text] [Related]
16. The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death.
Qiu P; Cui X; Barochia A; Li Y; Natanson C; Eichacker PQ
Expert Opin Investig Drugs; 2011 Nov; 20(11):1555-64. PubMed ID: 21961576
[TBL] [Abstract][Full Text] [Related]
17. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.
Jankovic J; Goodman I; Safirstein B; Marmon TK; Schenk DB; Koller M; Zago W; Ness DK; Griffith SG; Grundman M; Soto J; Ostrowitzki S; Boess FG; Martin-Facklam M; Quinn JF; Isaacson SH; Omidvar O; Ellenbogen A; Kinney GG
JAMA Neurol; 2018 Oct; 75(10):1206-1214. PubMed ID: 29913017
[TBL] [Abstract][Full Text] [Related]
18. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial.
Fisher CJ; Slotman GJ; Opal SM; Pribble JP; Bone RC; Emmanuel G; Ng D; Bloedow DC; Catalano MA;
Crit Care Med; 1994 Jan; 22(1):12-21. PubMed ID: 8124953
[TBL] [Abstract][Full Text] [Related]
19. Safety, potential efficacy, and pharmacokinetics of specific polyclonal immunoglobulin F(ab')₂ fragments against avian influenza A (H5N1) in healthy volunteers: a single-centre, randomised, double-blind, placebo-controlled, phase 1 study.
Bal C; Herbreteau CH; Buchy P; Rith S; Zaid M; Kristanto W; Han V; Reynaud C; Granjard P; Lépine B; Durand C; Tambyah PA
Lancet Infect Dis; 2015 Mar; 15(3):285-92. PubMed ID: 25662592
[TBL] [Abstract][Full Text] [Related]
20. Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trial.
François B; Luyt CE; Dugard A; Wolff M; Diehl JL; Jaber S; Forel JM; Garot D; Kipnis E; Mebazaa A; Misset B; Andremont A; Ploy MC; Jacobs A; Yarranton G; Pearce T; Fagon JY; Chastre J
Crit Care Med; 2012 Aug; 40(8):2320-6. PubMed ID: 22622405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
